The Neuroprotection Stack: Cerebrolysin + Semax

Research disclaimer: These compounds are sold for research purposes only and are not intended for human consumption.

Evidence Tier for This Combination

Strong by peptide standards — both compounds have human clinical trial data. Cerebrolysin has been through multiple RCTs for Alzheimer’s disease and stroke. Semax is an approved medicine in Russia for stroke and cognitive decline. The combination has not been studied in a controlled trial.

This is the highest-evidence peptide stack for cognitive neuroprotection in this guide series. The individual compound evidence is not marginal — Cerebrolysin has Cochrane reviews, and Semax has regulatory approval. Claiming the combination is proven in humans would still be overclaiming. But the individual foundations are real.

What These Compounds Are

Cerebrolysin

Cerebrolysin is a peptide mixture derived from purified pig brain proteins (predominantly from the cortex). It contains a complex mixture of low-molecular-weight peptides, many of which are biologically active analogs of endogenous neurotrophic factors including BDNF, NGF, CNTF, and GDNF. The exact composition varies slightly by batch, which is a limitation of any biological extract.

It is not a single sequenced peptide. This distinguishes it from everything else in this guide. Its activity is more akin to a neurotrophin cocktail than a defined pharmacological compound.

Human clinical data: Multiple RCTs for Alzheimer’s disease have been conducted, with systematic reviews and meta-analyses available. The results are mixed — some show meaningful cognitive improvement, particularly at higher doses; others show no significant effect versus placebo. Quality of trials varies substantially. The Cochrane review concluded that the evidence is insufficient to draw firm conclusions but noted that several trials showed benefit.

For stroke and vascular dementia, the evidence base is stronger. Cerebrolysin is used clinically in Austria (where it was developed), Germany, Russia, China, and throughout Asia and Eastern Europe.

Administration: Injection only — IV or IM. It cannot be taken orally (degraded in the GI tract). IV administration is used in clinical settings; IM is more practical for self-research.

Semax

Semax is a synthetic heptapeptide analog of ACTH(4-7) with a Pro-Gly-Pro C-terminal extension. Its primary mechanism is upregulation of BDNF and NGF — the same neurotrophins found in Cerebrolysin. The Pro-Gly-Pro extension significantly extends its half-life compared to native ACTH(4-7).

Unlike Cerebrolysin, Semax is a defined synthetic peptide with a known sequence and mechanism. It is administered intranasally. In Russia it is approved and prescribed for stroke recovery, traumatic brain injury, optic nerve disease, and cognitive decline.

Why They Work Together

Both compounds raise BDNF and NGF, but through different mechanisms:

Cerebrolysin delivers exogenous neurotrophin-like peptides that directly activate neurotrophin receptors (TrkB for BDNF, TrkA for NGF). The effect is more direct — you are providing the signal molecule itself, in peptide form, from outside the cell.

Semax induces endogenous neurotrophin synthesis — it stimulates the neuron’s own BDNF and NGF production via ACTH receptor-mediated intracellular signalling. The effect is more upstream and may take longer to manifest but engages the cell’s own regulatory machinery.

The combination provides both immediate exogenous neurotrophin signalling (Cerebrolysin) and upregulated endogenous production (Semax). These are complementary rather than redundant: one supplies the signal, the other upregulates the cell’s capacity to generate it. For sustained neuroprotection and neuroplasticity, having both pathways active is mechanistically sensible.

Additionally, Semax has dopaminergic effects that Cerebrolysin does not provide — contributing to motivated focus and working memory in a way that pure neurotrophin support does not.

Protocol

Cerebrolysin’s logistics are more demanding than Semax. It requires intramuscular or intravenous injection, comes in ampoules, and is temperature-sensitive.

Standard research protocol:

Cerebrolysin ampoule concentrations: Typically supplied as 1 mL or 2 mL ampoules at 215.2 mg/mL. A 5 mL dose requires combining multiple ampoules or using larger vials where available. The European clinical protocol for Alzheimer’s trials commonly used 10 mL/day IV — this is not practical for most research contexts and the IM route is used at lower volumes.

Timing: Morning administration is preferred for both compounds to align with natural cortisol rhythms and cognitive activity windows. Cerebrolysin has a relatively short plasma half-life (the complex peptide mixture clears quickly); its neurological effects persist longer through downstream neurotrophin signalling.

Dosing Table

The most practical research protocol stacks a 10–14 day Cerebrolysin IM course with a 21-day Semax intranasal course, overlapping from the start.

What the Evidence Supports

Cerebrolysin for acute stroke: Among the stronger indications. Several high-quality trials show functional improvement when administered within 24–72 hours of ischaemic stroke and continued for 10–21 days. This is clinical-grade evidence.

Cerebrolysin for Alzheimer’s: Mixed evidence. Some trials show meaningful cognitive improvement (particularly at 10 mL/day); the Cochrane review is cautious. The compound works best in earlier disease stages and with repeated cycles.

Semax for cognitive enhancement in healthy subjects: The evidence is weaker than for pathological states. Russian clinical data covers stroke and injury recovery. The assumption that BDNF upregulation improves cognition in a healthy brain is reasonable but not directly demonstrated in high-quality trials.

The neuroprotection framing: Both compounds are better evidenced as treatments for neurological disease and injury than as preventative neuroprotection in healthy individuals. The research application of this stack for healthy researchers extrapolates from clinical data obtained in patient populations.

What to Expect Realistically

During a Cerebrolysin course: Some researchers report improved verbal fluency, clearer thinking, and better recall within the first week. These effects are consistent with neurotrophin signalling but are also subject to expectation effects. The clinical data suggests genuine benefit in pathological states; the effect in healthy individuals is less certain.

Semax: Often produces noticeable effects within the first few doses — increased mental clarity and verbal fluency. These are among the more reliable subjective reports in the cognitive peptide literature.

Combined: The combination is used in Russian clinical practice for cognitive rehabilitation. The combined subjective profile — heightened neurotrophin signalling plus dopaminergic activation — is reported as clearer thinking, improved memory encoding, and sustained focus.

What this is not: A dramatic intelligence enhancer for healthy users. The human evidence is built on patient populations with actual neurological damage or disease. The effect ceiling in healthy subjects is unknown and likely lower.

Summary

Cerebrolysin and Semax represent the most evidence-dense neuroprotection stack available in the research peptide landscape. Both have human clinical data — real trials, real patient populations, real outcomes. The combination is mechanistically complementary (exogenous neurotrophin delivery + endogenous neurotrophin upregulation). Logistics are more demanding than most peptide stacks due to Cerebrolysin’s injection requirement and ampoule format. For researchers focused on BDNF-pathway neuroplasticity and cognitive preservation, this is where the evidence actually is.

See also: Semax data page · Cognitive Stack: Semax + Selank